Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. The post MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic' Data appeared first on InvestorPlace.

MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic' Data

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.

MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based on a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers and was published in Clinical Pharmacology and Therapeutics.

Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to psilocybin in humans. The publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers conducted by the University Hospital Basel Liechti Lab and sponsored by MindMed.

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Field Trip Health Ltd

Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.

3 Psychedelic Stocks for Potential Out-of-This-World Gains

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter ended Sept. 30, 2021. Q3 & Nine Months 2021 Financial Highlights Total assets were $178.6 million, including $145.9 million in cash, as compared to $85.6 million, including $80.1 million in cash, as of Dec. 31, 2020.

MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD

NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study"). Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response.

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights (in USD) Cash Balance.

MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.

MindMed to Present at the Jefferies London Healthcare Conference

COMPASS Pathways

Atai Life Sciences BV

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential

NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D.

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit , taking place on November 1-4, 2021 in Lisbon, Portugal. Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".

MindMed to Present at Web Summit on Future of Mental Health

NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD).  This program represents a significant expansion and diversification of MindMed's pipeline and furthers the Company's mission to bring innovative products to benefit patients and address unmet medical needs.

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

Their clinical programs and research-enabling technologies both surpass the competition.

These 4 Psychedelic Biotech Stocks Are Leading the Pack

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit , held virtually on October 26 - 27, 2021. "Digital biomarkers and digital measurements are an area of great interest in pharmaceutical development and the delivery of healthcare.

MindMed CMO to Chair Digital Biomarkers Summit

Cinedigm

VAALCO Energy

Globalstar

Romeo Power

Senseonics Holdings

Uranium Energy

So, which penny stocks should you buy, with the potential to break through the ceiling, en route to higher prices? Consider these seven top names that could do just that: Cinedigm (NASDAQ:CIDM) Vaalco Energy (NYSE:EGY) Globalstar (NYSEAMERICAN:GSAT) Mind Medicine (NASDAQ:MNMD) Romeo Power (NYSE:RMO) Senseonics (NYSEAMERICAN:SENS) Uranium Energy (NYSEAMERICAN:UEC) The post 7 Penny Stocks to Buy – While They're Still Penny Stocks appeared first on InvestorPlace.

7 Penny Stocks to Buy – While They're Still Penny Stocks

PharmaCyte Biotech

Sesen Bio Inc.

Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.

3 Penny Stocks Waiting on FDA Approval for Rocket Fuel

NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials. MindMed joins CTTI as one of approximately 80 member organizations interested in advancing higher quality clinical trials and accelerating the path to new therapeutics and other medical products.

MindMed Joins Clinical Trials Transformation Initiative

Asensus Surgical

Vinco Ventures

SNDL Inc.

Exela Technologies

They're not exactly names you want to bet the ranch on. Still, a $100 position in each of these penny stocks could be worth the risk.

7 Penny Stocks to Pick Up if You Have $100 to Spare

Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with certain mental illnesses. Under the strategic research collaboration, Sphere Health - a physician-founded employee benefits provider targeting treatments for people with severe mental illness – and MindMed are launching MM061302 in an attempt to develop more accurate machine learning tools to identify biomarkers that show association with and prediction of symptoms of anxiety and affective disorders.

MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression

NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphe re  Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders. MindMed and Sphere Health are jointly launching MM061302, a study using existing consumer technology to provide a robust data set, which may be used to develop more accurate machine learning tools in order to identify biomarkers that show association with and prediction of symptoms of anxiety and depression.

MindMed Announces Strategic Research Collaboration with Sphere Health

This article by Gaurav Dubey was originally published on Microdose Psychedelic Insights and appears here with permission. The psychedelic front-runners at MindMed (NASDAQ:MNMD) have announced their partnership with BioXcel Therapeutics and published an International Patent Application describing a system for identifying agitation episodes.

Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr.

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L.

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany.

News for Mind Medicine MindMed Stock (MNMD)